DMD and hereditary disease: As the dCas13 protein is large and difficult to apply for AAV delivery, a study reported a smaller RNA BE (ceRBE), which replaced the dCas13 protein with the EcCas6e protein, was able to achieve A to I and C to U base editing with low transcriptome off‐targeting, and in humanized DMD mice, AAV delivery of ceRBE could efficiently repair the DMD Q1392X mutation (68.3 ± 10.1%), confirming the potential application of ceRBE in the treatment of genetic diseases.361